Director and Board of Directors
HanchorBio is committed to establishing a robust, professional, and forward-looking corporate governance framework.
Our Board of Directors is composed of highly experienced industry experts who are responsible for defining the company’s strategic direction, overseeing operations, and safeguarding shareholders’ interests. Guided by the core principles of integrity, transparency, and accountability, we strive to ensure the company’s sustainable growth and long-term success.
In accordance with the Articles of Incorporation and relevant company regulations, HanchorBio’s Board of Directors consists of eight members, including three independent directors, to enhance governance transparency and oversight.
The Board is composed of professionals with diverse backgrounds spanning biotechnology and pharmaceuticals, regulatory affairs, finance, venture capital, and multinational corporate management.
- Postdoctoral Research in Biological Sciences, Stanford University
- Ph.D. in Molecular Biology and Microbiology, Department of Biological Sciences, Purdue University
- Vice President of R&D (Asia Region) and Director of Quality Operations & Regulatory Affairs, United Biomedical, Inc. (USA)
- Associate Director of Biologics Quality Control, Bristol Myers Squibb (BMS), USA
- Director of Analytical Quality Laboratories, Amgen, USA
- Founder and CEO, Shanghai Henlius Biotech (Fosun Pharma Group)
-
B.A. in Accounting, National Taiwan University
-
Associate Vice President, Anfu Capital Co., Ltd.
-
Director, Syncell Biomedical Co., Ltd.
-
Director, CompAstro Bioinformatics Co., Ltd.
-
Director, SoundOn Medical Co., Ltd.
-
Supervisor, UniCordis Biomedical Co., Ltd.
-
Certified Public Accountant (Taiwan)
-
Certified Securities Investment Analyst (CSIA), Taiwan
-
M.S. in Finance, Grand Canyon University, Phoenix, USA
-
Senior Vice President & Chief Financial Officer, Henlix Biotech Co., Ltd.
-
Senior Vice President & Chief Investment Officer, Taiwan Industrial Bank
-
Executive Vice President, Investment Management Division, JihSun Financial Holding Co., Ltd.
-
Senior Vice President, Chief of Staff & Chief Investment Officer, MasterLink Securities Corp.
B.Eng., The University of Hong Kong
Director, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Director, Beijing Tide Pharmaceutical Co., Ltd.
Director, Chia Tai Boai Investment Co., Ltd.
Director, Chia Tai Yeheng Biotechnology (Shanghai) Co., Ltd.
Chairman, Chia Tai Shaoyang Orthopedic Hospital
-
Master of Business Administration, Harvard Business School
-
Ph.D. in Neuroscience, University of California, San Francisco (UCSF)
-
M.S. in Cell Development and Physiology, University of California, Berkeley
-
B.S. in Biochemistry, University of California, Berkeley
-
CEO, HuidaGene Therapeutics Co., Ltd.
-
Scientific Advisor, Pfizer Ventures
-
B.A. in Accounting, Soochow University
-
Certified Public Accountant, Dewei & Co., CPAs
-
Ph.D. in Polymer Science and Engineering, University of Massachusetts Lowell, USA
-
Professor, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University
-
Legal Studies, The Dickson Poon School of Law, King’s College London, University of London
-
LL.B., Soochow University
-
Attorney, POSI Law Firm
-
Attorney, Chien Yeh Law Offices
-
Arbitrator, Chinese Arbitration Association, Taipei (CAA)
-
Ph.D. in Business Administration, National Central University
-
Independent Director, D-Link Corporation
-
Adjunct Assistant Professor, Department of Accounting, Soochow University
-
Chief Sustainability Consultant, BioVision Technology Co., Ltd.
Board Responsibilities and Operations
The Board of Directors is responsible for the following key functions:
-
Formulating the company’s business strategies and long-term development roadmap
-
Reviewing major financial budgets, fundraising plans, and investment proposals
-
Approving significant contracts and collaborations, such as technology licensing and R&D partnerships
-
Overseeing risk management, internal controls, and the implementation of disclosure practices
-
Appointing and evaluating the performance of senior management
-
Ensuring adherence to ethical conduct and ESG (Environmental, Social, and Governance) principles
The Board holds meetings on a regular basis and is supported by the Audit Committee and the Compensation Committee, which help enhance decision-making quality and ensure regulatory compliance.
Governance Commitment
HanchorBio adheres to the highest standards of integrity and transparency, and continuously enhances the effectiveness of its Board of Directors in accordance with corporate governance best practices. We actively engage with stakeholders and remain committed to creating long-term value for our shareholders.
